Multiple Sclerosis

- COMPliance With Avonex® PS in Patients with Relapsing-Remitting MS (COMPASS)

Principal Investigator: Dr. Yves Lapierre

- Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis (ENDORSE).

Principal Investigator: Dr. Amit Bar-Or

- Safety and Efficacy of Teriflunomide (HMR 1726) in Multiple Sclerosis With Relapses.

- TYSABRI® Global Observational Program Program in Safety (TYGRIS).

- A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

- Fingolimod in Primary Progressive Multiple Sclerosis (2306)

Principal Investigator: Dr. Jack Antel

- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (EPOC)

Principal Investigator : Dr. Jack Antel

- Safety and Efficacy of Ono-4641 in Patients with Relapsing-Remitting Multiple Sclerosis

Principal Investigator: Dr. Amit Bar-Or

Stroke

No ongoing trials at the present time.

Pain

No ongoing trials at the present time.

Epilepsy

- Trial to Assess Long-Term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-Onset Seizures. SP904

- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Principal Investigator: Eva Andermann

Migraine

No ongoing trials at the present time.

ALS (Lou Gehrig's Disease)

- Ceftriaxone in Subjects with ALS - Phase III

Principal Investigator: Dr. Angela Genge

- Phase 3 Study of Dexpramipexole in ALS (EMPOWER)

Principal Investigator: Dr. Angela Genge

- Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)

Principal Investigator : Dr. Angela Genge

Brain Tumor

- BIBW 2992 With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

-Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status (CORE)

Principal Investigator : Dr. Thierry Muanza

- Phase 3 trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma.

Other

- MAPS Trial: Matrix and Platinum Science for Aneurisms.

Revised April 22, 2012